Galectin‑3 induces the phenotype transformation of human vascular smooth muscle cells via the canonical Wnt signaling

Tian,Lei; Chen,Kan; Cao,Jiatian; Han,Zhihua; Wang,Yue; Gao,Lin; Fan,Yuqi; Wang,Changqian

doi:10.3892/mmr.2017.6429

Galectin‑3 induces the phenotype transformation of human vascular smooth muscle cells via the canonical Wnt signaling

Authors:
- Lei Tian
- Kan Chen
- Jiatian Cao
- Zhihua Han
- Yue Wang
- Lin Gao
- Yuqi Fan
- Changqian Wang
View Affiliations

Affiliations: Department of Cardiology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, P.R. China
Published online on: April 3, 2017 https://doi.org/10.3892/mmr.2017.6429
Pages: 3840-3846

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galectin‑3, a galactoside‑binding protein, is highly expressed in carotid plaques and plays an important role in the atherosclerotic lesions. The phenotype transformation of vascular smooth muscle cells is the basic pathological change of atherosclerosis. This study investigated the effects of exogenous galectin‑3 on the function and phenotype transformation of human umbilical vascular smooth muscle cells (HUSMC). In this study, we treated vascular smooth muscle cells with recombinant galectin‑3 and tested its effect on cell proliferation, migration, and phenotype transformation. Our results showed that exogenous galectin‑3 promoted human umbilical vascular smooth muscle cells (HUSMC) proliferation and migration. Exogenous galectin‑3 enhanced the expression of the smooth muscle synthetic protein osteopontin, smooth muscle contractile proteins calponin and smooth muscle α‑actin. The galectin‑3‑induced change in cell phenotype was associated with the activation of canonical Wnt signaling, as measured by β‑catenin axin2 and cyclin D1 expression. β‑catenin inhibition by small interfering RNA reduced cell proliferation, decreased cell motility, and blocked galectin‑3‑induced phenotype transformation of human umbilical vascular smooth muscle cells (HUSMC). Our data suggest galectin‑3 promotes the phenotype transformation of human umbilical vascular smooth muscle cells (HUSMC) by activating Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Lusis AJ: Atherosclerosis. Nature. 407:233–241. 2000. View Article : Google Scholar : PubMed/NCBI
2	Karagiannis GS, Weile J, Bader GD and Minta J: Integrative pathway dissection of molecular mechanisms of moxLDL-induced vascular smooth muscle phenotype transformation. BMC Cardiovasc Disord. 13:42013. View Article : Google Scholar : PubMed/NCBI
3	Doran AC, Meller N and McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 28:812–819. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hao H, Gabbiani G and Bochaton-Piallat ML: Arterial smooth muscle cell heterogeneity: Implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol. 23:1510–1520. 2003. View Article : Google Scholar : PubMed/NCBI
5	Kim K, Mayer EP and Nachtigal M: Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim Biophys Acta. 1641:13–23. 2003. View Article : Google Scholar : PubMed/NCBI
6	Markowska AI, Liu FT and Panjwani N: Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med. 207:1981–1993. 2010. View Article : Google Scholar : PubMed/NCBI
7	Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P and López-Andrés N: Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 33:67–75. 2013. View Article : Google Scholar : PubMed/NCBI
8	Dumic J, Dabelic S and Flögel M: Galectin-3: An open-ended story. Biochim Biophys Acta. 1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
9	Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
10	Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H and Raz A: Implication of galectin-3 in Wnt signaling. Cancer Res. 65:3535–3537. 2005. View Article : Google Scholar : PubMed/NCBI
11	Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung MC and Bresalier RS: Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 69:1343–1349. 2009. View Article : Google Scholar : PubMed/NCBI
12	Francia P, Adduci C, Semprini L, Borro M, Ricotta A, Sensini I, Santini D, Caprinozzi M, Balla C, Simmaco M and Volpe M: Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators. J Cardiovasc Electrophysiol. 25:609–616. 2014. View Article : Google Scholar : PubMed/NCBI
13	de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A and Pieske B: Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 15:1095–1101. 2013. View Article : Google Scholar : PubMed/NCBI
14	Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, et al: Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION study. Circ Heart Fail. 5:72–78. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mayr A, Klug G, Mair J, Streil K, Harrasser B, Feistritzer HJ, Jaschke W, Schocke M, Pachinger O and Metzler B: Galectin-3: Relation to infarct scar and left ventricular function after myocardial infarction. Int J Cardiol. 163:335–337. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sanchez-Mas J, Lax A, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, Pastor F, Januzzi JL and Pascual-Figal DA: Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol. 172:e98–e101. 2014. View Article : Google Scholar : PubMed/NCBI
17	van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP and Pinto YM: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 48:1217–1224. 2006. View Article : Google Scholar : PubMed/NCBI
18	Szadkowska I, Wlazel RN, Migala M, Bajon-Laskowska K, Szadkowski K, Zielińska M, Paradowski M and Pawlicki L: The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers. 18:655–659. 2013. View Article : Google Scholar : PubMed/NCBI
19	Nachtigal M, Ghaffar A and Mayer EP: Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol. 172:247–255. 2008. View Article : Google Scholar : PubMed/NCBI
20	Seferovic JP, Lalic NM, Floridi F, Tesic M, Seferovic PM, Giga V, Lalic K, Jotic A, Jovicic S, Colak E, et al: Structural myocardial alterations in diabetes and hypertension: The role of galectin-3. Clin Chem Lab Med. 52:1499–1505. 2014.PubMed/NCBI
21	Yilmaz H, Cakmak M, Inan O, Darcin T and Akcay A: Increased levels of galectin-3 were associated with prediabetes and diabetes: New risk factor? J Endocrinol Invest. 38:527–533. 2015. View Article : Google Scholar : PubMed/NCBI
22	Guyton JR, Lenz ML, Mathews B, Hughes H, Karsan D, Selinger E and Smith CV: Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants. Atherosclerosis. 118:237–249. 1995. View Article : Google Scholar : PubMed/NCBI
23	Leavesley DI, Schwartz MA, Rosenfeld M and Cheresh DA: Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol. 121:163–170. 1993. View Article : Google Scholar : PubMed/NCBI
24	Tickenbrock L, Schwäble J, Strey A, Sargin B, Hehn S, Baas M, Choudhary C, Gerke V, Berdel WE, Müller-Tidow C and Serve H: Wnt signaling regulates transendothelial migration of monocytes. J Leukoc Biol. 79:1306–1313. 2006. View Article : Google Scholar : PubMed/NCBI
25	Schaale K, Neumann J, Schneider D, Ehlers S and Reiling N: Wnt signaling in macrophages: Augmenting and inhibiting mycobacteria-induced inflammatory responses. Eur J Cell Biol. 90:553–559. 2011. View Article : Google Scholar : PubMed/NCBI
26	Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ and Raz A: Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 156:899–909. 2000. View Article : Google Scholar : PubMed/NCBI
27	Jia W, Kidoya H, Yamakawa D, Naito H and Takakura N: Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol. 182:1821–1831. 2013. View Article : Google Scholar : PubMed/NCBI
28	Carthy JM, Luo Z and McManus BM: WNT3A induces a contractile and secretory phenotype in cultured vascular smooth muscle cells that is associated with increased gap junction communication. Lab Invest. 92:246–255. 2012. View Article : Google Scholar : PubMed/NCBI
29	Rensen SS, Doevendans PA and van Eys GJ: Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 15:100–108. 2007. View Article : Google Scholar : PubMed/NCBI
30	Matsushita T, Rama A, Charolidi N, Dupont E and Severs NJ: Relationship of connexin43 expression to phenotypic modulation in cultured human aortic smooth muscle cells. Eur J Cell Biol. 86:617–628. 2007. View Article : Google Scholar : PubMed/NCBI
31	Rama A, Matsushita T, Charolidi N, Rothery S, Dupont E and Severs NJ: Up-regulation of connexin43 correlates with increased synthetic activity and enhanced contractile differentiation in TGF-beta-treated human aortic smooth muscle cells. Eur J Cell Biol. 85:375–386. 2006. View Article : Google Scholar : PubMed/NCBI
32	Menini S, Iacobini C, Ricci C, Fantauzzi C Blasetti, Salvi L, Pesce CM, Relucenti M, Familiari G, Taurino M and Pugliese G: The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 100:472–480. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, Tsutsumi S, Suzuki H, Kuwano H and Raz A: Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer. 129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
34	Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin M, Bao SS, Hu YW and Wei FC: Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating β-catenin. Acta Pharmacol Sin. 34:176–184. 2013. View Article : Google Scholar : PubMed/NCBI